Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
133.96(c) 135.21(c) 136.55(c) 134.63(c) 133.4(c) Last
922 250 1 033 348 1 169 095 1 197 609 1 413 361 Volume
+0.77% +0.93% +0.99% -1.41% -0.91% Change
More quotes
Financials ($)
Sales 2017 3 526 M
EBIT 2017 1 532 M
Net income 2017 739 M
Debt 2017 1 352 M
Yield 2017 -
Sales 2018 4 078 M
EBIT 2018 1 913 M
Net income 2018 1 112 M
Finance 2018 161 M
Yield 2018 -
P/E ratio 2017 39,58
P/E ratio 2018 26,03
EV / Sales2017 8,83x
EV / Sales2018 7,26x
Capitalization 29 773 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
08/17 ALEXION PHARMACEUTICALS : Patent Issued for Treatment of Paroxysmal Nocturnal He..
08/16 ALEXION PHARMACEUTICALS : Update in Lawsuit for Investors in NASDAQ: ALXN Shares..
08/16 ALEXION PHARMACEUTICALS : Receives Three New U.S. Patents for Soliris, Extending..
08/15 ALEXION PHARMACEUTICALS : Receives Three New U.S. Patents for Soliris® (eculizum..
08/14 ALEXION PHARMACEUTICALS : And Sema4 Partner In Rare Disease Diagnostics And Syst..
08/10 ALEXION PHARMACEUTICALS : Patent Issued for Treatment of Paroxysmal Nocturnal He..
08/10 ALEXION PHARMACEUTICALS : and Sema4 Partner in Rare Disease Diagnostics and Syst..
08/03 INSIDER TRADING ACTIVITY ALEXION PHA : ALXN) – Director Sold 700 shares of..
07/27 ALEXION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
07/27 ALEXION PHARMACEUTICALS, INC. (NASDA : ALXN) reported earnings of $1.56 per shar..
More news
Sector news : Biopharmaceuticals
08/18DJCorrection to Biogen Treads Tricky Path Between Politicians, Investors Articl..
08/18DJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08/18DJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
More sector news : Biopharmaceuticals
Latest Tweets
08/18Tracking John Paulson's Paulson & Company Portfolio - Q2 2017 Update  
08/18Tracking John Paulson's Paulson & Company Portfolio - Q2 2017 Update  
08/17State of Wisconsin Investment Board Boosts Stake in Alexion Pharmaceuticals, .. 
08/16Alexion Pharmaceuticals, Inc. $ALXN Now Covered by Analysts at Evercore ISI  
08/16Alexion Pharmaceuticals initiated by Evercore ISI at . $137.00 PT.  
More tweets
Qtime:226
News from SeekingAlpha
08/18 Tracking John Paulson's Paulson & Company Portfolio - Q2 2017 Update
08/17 Evercore ISI initiates 14 bullish calls, 9 neutral
08/15 Alexion lands three U.S. patents covering Soliris
08/15 Waiting For A Pullback In Alexion Pharmaceuticals
08/14 New positions at Third Point
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 159 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Julie O'Neill Executive Vice President-Global Operations
Paul J. Clancy Chief Financial Officer
John J. Orloff Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS9.03%29 773
BIOGEN7.82%60 135
CSL LIMITED26.48%45 524
GRIFOLS SA23.33%17 290
BIOMARIN PHARMACEUTICAL-2.32%14 193
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%5 594